SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000921895-20-000244
Filing Date
2020-02-04
Accepted
2020-02-04 17:22:12
Documents
2

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO THE SCHEDULE 13D sc13da507422010_02042020.htm SC 13D/A 326163
2 JOINT FILING AGREEMENT ex992to13da507422010_020420.htm EX-99.2 10147
  Complete submission text file 0000921895-20-000244.txt   337991
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Subject) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-48459 | Film No.: 20574959
SIC: 2834 Pharmaceutical Preparations

Mailing Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Business Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

IRS No.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice